Antagonism of cysteinyl leukotrienes and their receptors as a neuroinflammatory target in Alzheimer’s disease

被引:0
作者
Rakesh Kumar Singh
机构
[1] National Institute of Pharmaceutical Education and Research,Department of Pharmacology and Toxicology
[2] Raebareli,undefined
来源
Neurological Sciences | 2020年 / 41卷
关键词
Alzheimer’s disease; Cysteinyl leukotrienes; Inflammatory cytokines; Chronic neuroinflammation; CysLT; antagonist;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2081 / 2093
页数:12
相关论文
共 433 条
[1]  
Cummings J(2014)Alzheimer’s disease drug development pipeline: 2018 Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 195-214
[2]  
Lee G(2017)Alzheimer’s disease: as it was in the beginning Rev Neurosci 28 825-843
[3]  
Rittera A(2016)Alzheimer’s disease mechanisms and emerging roads to novel therapeutics Annu Rev Neurosci 39 57-59
[4]  
Zhong K(2017)Molecular pathogenesis of Alzheimer’s disease: an update Ann Neurosci 24 46-54
[5]  
Kozlov S(2015)Reducing Aβ load and tau phosphorylation: emerging perspective for treating Alzheimer’s disease Eur J Pharmacol 764 571-581
[6]  
Afonin A(2015)The combined treatment of amyloid-β1-42-stimulated bone marrow–derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer’s disease in APPswe/PSENldE9 mice Neurobiol Aging 36 111-122
[7]  
Evsyukov I(2016)Molecular and cellular pathophysiology of preclinical Alzheimer’s disease Behavioral Brain Research 311 54-69
[8]  
Bondarenko A(2017)A systemic view of Alzheimer disease - insights from amyloid-β metabolism beyond the brain Nat Rev Neurol 13 612-623
[9]  
Sala Frigerio C(2015)Neuroinflammation in Alzheimer’s disease Neuropsychiatr Dis Treat 11 243-256
[10]  
De Strooper B(2012)Montelukast potentiates the protective effect of rofecoxib against kainic acid-induced cognitive dysfunction in rats Pharmacol Biochem Behav 103 43-52